Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery
Open Access
- 17 August 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e000207
Abstract
Background: Glioblastoma (GBM) treatment is undermined by the suppressive tumor immune microenvironment (TIME). Seek for effective methods for brain TIME modulation is a pressing need. However, there are two major challenges against achieving the goal: first, to screen the effective drugs with TIME-remodeling functions and, second, to develop a brain targeting system for delivering the drugs. Methods: In this study, an α7 nicotinic acetylcholine receptors (nAChRs)-binding peptide DCDX was used to modify the codelivery liposomes to achieve a ‘three-birds-one-stone’ delivery strategy, that is, multi-targeting the glioma vessel endothelium, glioma cells, and tumor-associated macrophages that all overexpressed α7 nAChRs. A brain-targeted liposomal honokiol and disulfiram/copper codelivery system (CDX-LIPO) was developed for combination therapy via regulating mTOR (mammalian target of rapamycin) pathway for remodeling tumor metabolism and TIME. Honokiol can yield a synergistic effect with disulfiram/copper for anti-GBM. Results: It was demonstrated that CDX-LIPO remarkably triggered tumor cell autophagy and induced immunogenic cell death, and meanwhile, activated the tumor-infiltrating macrophage and dendritic cells, and primed T and NK (natural killer) cells, resulting in antitumor immunity and tumor regression. Moreover, CDX-LIPO promoted M1-macrophage polarization and facilitated mTOR-mediated reprogramming of glucose metabolism in glioma. Conclusion: This study developed a potential combinatory therapeutic strategy by regulation of TIME and a ‘three-birds-one-stone’-like glioma-targeting drug delivery system.Keywords
Funding Information
- National Natural Science Foundation of China (81925035, 81673382 and 81521005)
This publication has 48 references indexed in Scilit:
- Role of mTOR Signaling in Tumor Microenvironment: An OverviewInternational Journal of Molecular Sciences, 2018
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- mTORC1 and mTORC2 as regulators of cell metabolism in immunityFEBS Letters, 2017
- Immune microenvironment of gliomasLaboratory Investigation, 2017
- The network of immunosuppressive pathways in glioblastomaBiochemical Pharmacology, 2017
- The role of microglia and macrophages in glioma maintenance and progressionNature Neuroscience, 2015
- Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questionsNeuro-Oncology, 2015
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Honokiol-mediated Inhibition of PI3K/mTOR PathwayJournal of Immunotherapy, 2009
- Microglia in brain tumorsGlia, 2002